Clinical characteristics, treatments, and outcomes of hematogenous pyogenic vertebral osteomyelitis, 12-year experience from a tertiary hospital in central Taiwan

J Microbiol Immunol Infect. 2018 Apr;51(2):235-242. doi: 10.1016/j.jmii.2017.08.002. Epub 2017 Aug 19.

Abstract

Background: In Taiwan, studies about hematogenous pyogenic vertebral osteomyelitis (HPVO) are limited. We conducted a retrospective study to evaluate the clinical presentations, treatment, and outcomes of patients with the diagnosis of HPVO.

Method: This 12.5-year retrospective study included patients with a diagnosis of HPVO. Medical records of all HPVO patients were thoroughly reviewed and their clinical data were analyzed by the SPSS software.

Result: 414 HPVO cases were included and the mean age was 61.6 ± 13.4 years. The mean duration of symptoms was 29 ± 35.3 days and pain over the affected site was reported by most patients (86.0%). Gram-positive bacteria, especially Staphylococcus aureus (162/399 = 40.6%), were the main HPVO pathogens. Escherichia coli (42/399 = 10.5%) was the most common gram-negative isolate. Surgery was performed in 68.8% of cases and the mean duration of total antibiotic treatment was 104.7 ± 77.7 days. All-cause mortality and recurrence rates were 6.3% and 18.8%, respectively. In multivariate analysis, polymicrobial infection (OR: 4.154, 95% CI: 1.039-16.604, p = 0.044), multiple vertebral body involvement (OR: 2.202, 95% CI: 1.088-4.457, p = 0.028), abscess formation treated with antibiotics alone (OR: 2.912, 95% CI: 1.064-7.966, p = 0.037), and the duration of antimicrobial treatment less than 4 weeks (OR: 3.737, 95% CI: 1.195-11.683, p = 0.023) were associated with HPVO recurrence.

Conclusion: In Taiwan, HPVO mainly affected the elderly and S. aureus remained the most common HPVO pathogen. In patients with risk factors associated with HPVO recurrence, a longer duration (≥6 weeks) of antimicrobial therapy is suggested.

Keywords: Hematogenous; Osteomyelitis; Pyogenic; Spine; Spondylitis.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Escherichia coli / isolation & purification*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Osteomyelitis / diagnosis
  • Osteomyelitis / microbiology*
  • Osteomyelitis / therapy
  • Recurrence
  • Retrospective Studies
  • Risk Factors
  • Spine / microbiology
  • Spine / pathology*
  • Staphylococcus aureus / isolation & purification*
  • Taiwan
  • Tertiary Care Centers
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents